Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vaxcyte Inc. Common Stock (PCVX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Vaxcyte Inc. Common StockTrade
YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Vaxcyte Inc. Common Stock vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.24 (market cap $297.21M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 35.4× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.

PCVXYMAG
Market Cap
$10.51B$297.21M
Volume
2,644,694809,569
Sector
HealthIncome / Options Overlay
52-Week High
$73.82$15.68
52-Week Low
$40.32$10.76
Typical Hold Time
0 Days62 Days
Enterprise Value
$9.14B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vaxcyte Inc. Common Stock

No Aura AI signal available yet.

YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG trades at $11.55, up 0.7% today, with a neutral technical signal and bullish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. RSI levels show mixed signals with short-term overbought conditions. Support and resistance levels are tightly clustered around $11-$12, indicating potential for near-term consolidation.

The outlook remains balanced with high distribution yields providing income appeal, though technical indicators suggest limited near-term momentum. Key risks include NAV stability during earnings periods and dependency on underlying option strategies. Analyst coverage is limited, requiring careful monitoring of component fund performance and distribution sustainability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PCVX
100% Buy0% Sell
Avg holding period · 0 Days
YMAG
100% Buy0% Sell
Avg holding period · 62 Days

Top news

Latest headlines on both assets

About Vaxcyte Inc. Common Stock

Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.

Read more on PCVX →

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.

Read more on YMAG →